Blau Farmacêutica S.A

What it is

Marcelo Hahn founded Blau Farmacêutica in 1987, choosing to focus on the segment of the Brazilian pharmaceutical market that most other local companies avoided: complex, hospital-grade drugs. The company develops, produces, and sells medicines for oncology, nephrology, hematology, and infectology, among other specialties, with a portfolio spanning biopharmaceuticals, biosimilars, blood products, antivirals, anaesthetics, and antithrombotics.

Based in Cotia, São Paulo, and employing roughly 1,700 people, Blau runs five industrial plants dedicated to biological, biotechnological, and oncological medicines. International expansion began in 2014 with a subsidiary in Uruguay; Blau now has commercial operations in Argentina, Colombia, Chile, Ecuador, and Peru as well.

Who owns it

Marcelo Rodolfo Hahn is the formally identified controlling shareholder, and holds his stake partly through his vehicle Hahn Participações Ltda. Insiders — overwhelmingly Hahn himself — hold about 82.5% of the shares, per EODHD data; institutions account for a further 9.9%, leaving a free float of roughly 7.6% (our calculation).

Blau listed on the Novo Mercado segment of B3 in April 2021.

The shares were priced at R$40.14 (US$8)at IPO and the company was valued at R$7.2bn (US$1.4 bn); today it is worth about R$2.2bn (US$426 mn) — a gap that Hahn acknowledges openly and attributes in part to the short-term orientation of Brazilian equity investors.

Who runs it

Marcelo Hahn remains founder, board member, and CEO, responsible for defining the company’s overall direction, new business strategy, and expansion plan both nationally and internationally. Rodolfo Hahn has been a member of the Board of Directors since 2011 and currently serves as its chairman.

Douglas Leandro Rodrigues serves as Chief Financial and Investor Relations Officer. The broader executive bench includes a Chief Technology & Digital Transformation Officer (Vanderlei Schiavo), a Chief Legal Officer (Roberto Altieri), and a Chief M&A and Operations Officer for the US and Europe (Roberto Carlos de Campos Morais).

The money, in plain words

Sales rose 27.8% in 2024 to a record R$1.75bn (US$339m) (our calculation), then dipped 3.0% in 2025 to R$1.70bn (US$329m) (our calculation) as the company digested acquisitions and absorbed higher structural investment costs. The 2024 revenue of R$1.75bn (US$339 mn) was a record and represented annual growth of 28% versus 2023.

For every real of sales, Blau keeps about 17.3 cents as net profit in its most recently completed year (FY2025 net margin: 17.3%, our calculation) — a meaningful recovery from 12.4% in FY2024. For every real shareholders have put in, it earns about 11 back per year — a return on equity of 10.9%, solid but below the double-digit cost of equity in Brazil’s high-interest environment.

At a price-to-earnings ratio of 10.8×, the stock is inexpensive relative to its sector, though the thin free float dampens liquidity.

The balance sheet is conservative: net debt stands at R$554m (US$107m) against equity of R$2.27bn (US$440m), a ratio of about 0.24× — a light load for a company investing heavily in new capacity (our calculation). The company ended 2024 with net debt of just R$24m (US$5 mn) and leverage of 0.1×, down from R$163m (US$32 mn) in 2023.

What it is doing now

Blau has announced R$1.2bn (US$232 mn) in investment in a new production facility in Pernambuco, to be financed from operating cash flow and built in phases. Construction was expected to begin in the second quarter of 2025, with the first phase — covering 30% of total planned output — to be delivered within two years.

In October 2025, the company received €52.1m (roughly R$325.5m (US$63 mn)) from the sale of its stake in Prothya, a European plasma-derived medicines company, compared with an original investment of R$265.2m (US$51 mn) — a profitable exit. Blau is also entering Mexico, where it is registering its medicines with the health regulator, adding a new country to its Latin American footprint.

What to watch

• Biosimilar pipeline: Blau has a partnership with US firm Similis Bio to develop four next-generation monoclonal antibody products whose patents begin expiring from 2028 — medicines no other Brazilian company currently produces.
• Pernambuco plant execution: A R$1.2bn (US$232 mn) multi-phase build is large relative to annual cash generation; any delay or cost overrun would pressure both margins and the balance sheet.
• Nasdaq ambition: Hahn has stated a plan to grow revenue in hard currency and eventually list Blau on the Nasdaq. Progress on international sales — currently about 10% of revenue — is the metric to track.
• Regulatory risk: Blau won two favourable Supreme Court rulings restoring the sector’s regulatory framework in the public procurement market — a positive, but government pricing decisions remain a structural swing factor.
• Free-float thinness: With roughly 7.6% of shares freely traded, even modest institutional flows move the price sharply — a feature, not a bug, for a patient long-term holder but a real risk for anyone needing to exit quickly.

This is news, not investment advice.